lacosamide
Sign in to saveAlso known as ADD 234037, erlosamide, harkeroside, SPM 927, Vimpat®, Erlosamide, Harkoseride
Lacosamide, sold under the brand name Vimpat among others, is a medication used for the treatment of Focal-onset seizures and primary generalized tonic-clonic seizures. It is used by mouth or intravenously.
Research
1,615 papers- Lacosamide.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2007
- Lacosamide in status epilepticus: Systematic review of current evidence.Epilepsia · 2017
- Lacosamide add-on therapy for focal epilepsy.The Cochrane database of systematic reviews · 2021
- Lacosamide and epilepsy.CNS neuroscience & therapeutics · 2011
- The adverse-effect profile of lacosamide.Expert opinion on drug safety · 2020
via PubMed
~12 min read
Encyclopedic overview
26 sectionsContents
- Medical uses
- Off-label use
- Contraindications
- Side effects
- Gastrointestinal
- Central nervous system
- Psychiatric
- Cardiovascular
- Allergies
- Warnings
- In pregnancy
- Overdose
- Pharmacology
- Pharmacodynamics
- Preclinical research
- Pharmacokinetics
- Chemistry
- Synthesis
- History
- Partial-onset seizures
- Peripheral neuropathy
- Society and culture
- Names
- Research
- References
- Further reading
Lacosamide, sold under the brand name Vimpat among others, is a medication used for the treatment of Focal-onset seizures and primary generalized tonic-clonic seizures. It is used by mouth or intravenously.
It is available as a generic medication.
Excerpted from Wikipedia’s “lacosamide” article, available under the CC BY-SA 4.0 licence.